JB/CALL/GILEAD SCIENCES/75/0.05/21.03.25 | Market Closed - Swiss Exchange 11:20:00 2024-07-16 am EDT | ||
| 0.23 CHF | +9.52% |
|
| 1 month | +109.09% | ||
| 3 months | +9.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.23 | +9.52% |
| 24-07-15 | 0.21 | +5.00% |
| 24-07-12 | 0.2 | +5.26% |
| 24-07-11 | 0.19 | +18.75% |
Delayed Quote Swiss Exchange
Last update July 16, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Bank Julius Bär |
| GIYEJB | |
| ISIN | CH1303727544 |
| Date issued | 2023-11-28 |
| Strike | 75 $ |
| Maturity | 2025-03-21 (248 Days) |
| Parity | 20 : 1 |
| Emission price | 0.4 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.75 CHF |
|---|---|
| Lowest since issue | 0.1 CHF |
| Spread | 0.01 CHF |
| Spread % | 4.17% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
71.64
USD
Average target price
83.01
USD
Spread / Average Target
+15.86%
- Stock Market
- Warrants
- GIYEJB Warrant
